Bio-innovators and entrepreneurs are often frustrated that investors don’t see the scope of biological opportunity. The industry’s funding models remain in flux. With appetite for risk unpredictable and a landscape that’s often unexplored, what’s a startup to do? How are big companies responding? In this video, Paul Gurney of McKinsey & Company moderates a discussion with Beth Seidenberg of Kleiner Perkins Caufield & Byers, Lindy Fishburne of Breakout Labs and the Thiel Foundation, and Steve Jurvetson of Draper Fisher Jurvetson and Synthetic Genomics, Inc.
To read the original article: The Funding Dilemma for Bio Innovators — Kleiner Perkins Caufield Byers
